Venturing into the world of psychedelic drug development, research, investing, and more. Sharing insights and interviewing leading figures in the field.
“Psychedelics will also get a dedicated session: a fireside chat with German billionaire investor @C_Angermayer , the founder and chair of psychedelics company @ataibeckley.”
$ATAI
I have cash sitting on the sidelines to buy names I view as being undervalued in the neuropsychiatry space.
Tickers I am looking at include $ATAI, $CYBN, $VTGN, $ANRO, $DRUG, $NEUP.
I am already overweight $ATAI, but the news-flow I am anticipating in the coming months makes me
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
$ATAI
Jake here: Like Christian, I am also biased towards $ATAI.
I too wonder what BPL-003 alone should be valued. Later stage than Gilgamesh program, larger dataset, in harder to treat depression, and superior drug delivery technology (IMO).
Awesome overview of @atai_life 👇
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
$ATAI
“There are ongoing clinical trials that are going to read out, sometime soon, and we have to take an expeditious and rapid review of that data”
- FDA commissioner, Dr. Marty Makary
$GHRS$MNMD$CMPS$ATAI$CYBN
Looking forward to seeing 12-month data from $CYBN tomorrow.
- Curious to see if 16 mg and 12 mg cohorts are both included in the data.
- Although this will be a small sample size, I am excited to see…. 12 month data. I think that if “even” 20-25% of trial participants are
